TransMedics Group, Inc. Stock News

SAN FRANCISCO, Feb. 28, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy, alleging that the company and certain executives engaged in fraudulent practices and concealed safety issues. The suit, captioned Jewik v.

TransMedics Group, Inc. (NASDAQ:TMDX ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President and Chief Executive Officer Gerardo Hernandez - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Josh Jennings - TD Cowen Bill Plovanic - Canaccord Suraj Kalia - Oppenhe...

TransMedics Group (TMDX -2.22%), a leader in organ transplant technology, released its fourth-quarter results on Feb. 27. The company reported diluted earnings per share (EPS) of $0.19, outpacing the $0.16 forecast by analysts, and revenue of $121.6 million exceeded the $109 million estimate.

NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purcha...

ANDOVER, Mass. , Feb. 27, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2024.

SAN FRANCISCO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy, alleging that the company and certain executives engaged in fraudulent practices and concealed safety issues. The suit, captioned Jewik v.

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In TransMedics To Contact Him Directly To Discuss Their Options